IntelliPharmaCeutics is a drug delivery developer, specializing in the controlled and targeted once-a-day delivery of oral, solid dose pharmaceutical products.
Started in 1988, it operates from a 25,000 sq ft research laboratory and manufacturing scale-up facility located adjacent to Toronto International Airport. The Company utilizes proprietary, patented and proven drug delivery technologies, to formulate both generic and new drug products with enhanced performance characteristics. In addition to its pre-clinical portfolio, IntelliPharmaCeutics has an extensive pipeline of development products in clinical trials, in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection.
Chief Scientists, Dr. Isa Odidi and Dr. Amina Odidi, are the inventors of each of the diverse core drug delivery technologies which the company now successfully exploits. They were also directly responsible for the design, development and advancement to production scale of each of the ten FDA-approved and commercially successful drugs and dosage strengths now on sale in the United States.
Par Pharmaceutical Makes Equity Investment in IntelliPharmaCeutics - 07-09-07 00:27